NCT02471313View on ClinicalTrials.gov

Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 12, 2015

Primary Completion Date

March 7, 2018

Study Completion Date

March 7, 2018

Conditions
Liver CancerLiver NeoplasmHepatocellular CarcinomaHCC
Interventions
DRUG

[18F] FMISO

\[18F\] Fluromisonidazole, 1 h-(3-\[18F\]-fluro-2hydroxyl-propy10-2-nitro-imidazaole is an investigational positron emission tomography (PET) radiopharmaceutical for injection and used to visualize hypoxia imaging agent. Each patient will receive up to 10 mCi of \[18F\] FMISO PET imaging post TACE procedure.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institutes of Health Clinical Center (CC)

NIH

NCT02471313 - Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization | Biotech Hunter | Biotech Hunter